Discovery and evaluation of protein biomarkers as a signature of wellness in late-stage cancer patients in early phase clinical trials
Thistlethwaite, Fiona C
Krebs, Matthew G
Whetton, Anthony D
AffiliationStoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester
MetadataShow full item record
AbstractTARGET (tumour characterisation to guide experimental targeted therapy) is a cancer precision medicine programme focused on molecular characterisation of patients entering early phase clinical trials. Performance status (PS) measures a patient's ability to perform a variety of activities. However, the quality of present algorithms to assess PS is limited and based on qualitative clinician assessment. Plasma samples from patients enrolled into TARGET were analysed using the mass spectrometry (MS) technique: sequential window acquisition of all theoretical fragment ion spectra (SWATH)-MS. SWATH-MS was used on a discovery cohort of 55 patients to differentiate patients into either a good or poor prognosis by creation of a Wellness Score (WS) that showed stronger prediction of overall survival (p = 0.000551) compared to PS (p = 0.001). WS was then tested against a validation cohort of 77 patients showing significant (p = 0.000451) prediction of overall survival. WS in both sets had receiver operating characteristic curve area under the curve (AUC) values of 0.76 (p = 0.002) and 0.67 (p = 0.011): AUC of PS was 0.70 (p = 0.117) and 0.55 (p = 0.548). These signatures can now be evaluated further in larger patient populations to assess their utility in a clinical setting.
CitationGeary B, Peat E, Dransfield S, Cook N, Thistlethwaite F, Graham D, et al. Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. Cancers. 2021 May 18;13(10):2443.
- Applying 'Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra' (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry.
- Authors: Arnhard K, Gottschall A, Pitterl F, Oberacher H
- Issue date: 2015 Jan
- Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients.
- Authors: Geary B, Walker MJ, Snow JT, Lee DCH, Pernemalm M, Maleki-Dizaji S, Azadbakht N, Apostolidou S, Barnes J, Krysiak P, Shah R, Booton R, Dive C, Crosbie PA, Whetton AD
- Issue date: 2019 Sep 6
- Comprehensive MS/MS profiling by UHPLC-ESI-QTOF-MS/MS using SWATH data-independent acquisition for the study of platelet lipidomes in coronary artery disease.
- Authors: Schlotterbeck J, Chatterjee M, Gawaz M, Lämmerhofer M
- Issue date: 2019 Jan 10
- Optimization of Acquisition and Data-Processing Parameters for Improved Proteomic Quantification by Sequential Window Acquisition of All Theoretical Fragment Ion Mass Spectrometry.
- Authors: Li S, Cao Q, Xiao W, Guo Y, Yang Y, Duan X, Shui W
- Issue date: 2017 Feb 3
- Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
- Authors: Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ, ACS and GC6–74 cohort study groups.
- Issue date: 2019 Apr